The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Development Of A Low-cost, Very Low-radiation Community-based Screening Method For Primary Prevention Of Cardiovascular Disease
Funder
National Health and Medical Research Council
Funding Amount
$419,180.00
Summary
Virtually everyone's life has been affected by cardiovascular disease (CVD) in some way. There are no routine community-based tests to identify asymptomatic CVD due to current tests being invasive, expensive, time-consuming or high radiation exposure. A low cost, very low radiation test from existing machines used for osteoporosis screening can assess a measure of asymptomatic CVD. This fellowship seeks to develop this test for community-based screening strategies.
Clinical Approaches To Preventing Cardiovascular Disease
Funder
National Health and Medical Research Council
Funding Amount
$463,652.00
Summary
Cardiovascular disease (CVD) is the leading cause of death and disease burden globally. While many new treatments have been discovered in the last few decades to prevent CVD, surveys show many people do not receive these treatments. Dr. Chow is committed to using her skills as a cardiologist and a researcher to bridge this gap. Her program aims to identify novel, simple and scalable approaches to decrease the gap in preventative care and reduce the burden of CVD in Australia and beyond.
Improving Prevention Of Cardiovascualr Disease In High Risk Populations
Funder
National Health and Medical Research Council
Funding Amount
$408,388.00
Summary
Heart attack and stroke are the leading causes of death and disease burden globally. While there are highly effective treatments to prevent cardiovascular disease, surveys in Australia and other parts of the world indicate they are not being taken up. This program of research aims to improve prevention in individuals at high risk of heart attack and stroke by developing and testing strategies to increase the use of effective evidence-based treatment therapies.
Provision Of Secondary Cardiac Preventive Australian General Practice
Funder
National Health and Medical Research Council
Funding Amount
$499,513.00
Summary
This study will provide a comprehensive description of secondary preventative activities for patients with ischaemic heart disease, with the aim of determining those factors that can most contribute to reducing the increased risk of further events which they experience, and thereby reducing the burden of this disease.
A Dual Antigen Synthetic Peptide Subunit Vaccine Approach To Prevent Streptococcal Associated Cardiovascular Disease
Funder
National Health and Medical Research Council
Funding Amount
$604,017.00
Summary
Infection with streptococcus is responsible for causing more than 500,000 deaths each year, the majority of which are due to rheumatic fever and rheumatic heart disease, which contributes to cardiovascular disease. Our research is aimed at the development of a vaccine to prevent heart disease and involves targeting multiple molecules present on the bacterial surface. We will use a novel vaccine delivery system developed in the laboratory, which will enable the vaccine to be delivered nasally.
Triple Therapy Prevention Of Recurrent Intracerebral Disease EveNts Trial (TRIDENT)
Funder
National Health and Medical Research Council
Funding Amount
$5,256,292.00
Summary
Acute intracerebral haemorrhage (ICH) is a serious form of stroke. Survivors of ICH are at high risk of repeat events. Blood pressure lowering is a very important to prevent repeat events but data shows blood pressure is poorly controlled in these patients. In this research we investigate whether an approach that uses a 'triple pill' strategy (3 low dose BP drugs in one pill) in ICH patients with mild to moderate hypertension can decrease major cardiovascular events.
Early Molecular Causes Of Pathological Cardiac Hypertrophy And Failure
Funder
National Health and Medical Research Council
Funding Amount
$311,860.00
Summary
Pathological increase in heart size is a common condition in Australia. Small regulatory RNAs are now known to have a role in the normal development of the heart. Therefore we want to identify and then test the use of small RNA molecules as prevention and therapy for heart enlargement in an animal model. We will also identify different combinations of changes in the DNA sequence that could be used as markers for the predisposition of increased heart.
Stroke Outcomes Following Catheter Ablation In Patients With Atrial Fibrillation
Funder
National Health and Medical Research Council
Funding Amount
$408,353.00
Summary
Atrial fibrillation is the most common heart rhythm disorder encountered in clinical practice. It is an irregular rhythm that predisposes individuals to stroke. Recently, catheter ablation has been shown to be successful in controlling this irregular rhythm. My research will investigate whether this treatment will decrease the risk of stroke in patients with atrial fibrillation by following a large cohort of patients after catheter ablation compared to those who have not underwent the procedure.
Quadruple UltrA-low-dose TReamenT For HypErTension - QUARTET
Funder
National Health and Medical Research Council
Funding Amount
$1,242,865.00
Summary
High blood pressure is common and a major cause of heart disease and stroke. While many people with hypertension are on some treatment, in over half blood pressure targets are not reached and their high blood pressure is hence uncontrolled. In this research we investigate whether an approach that combines 4 types of blood pressure lowering medications at quarter doses into one pill, may be a more effective way of controlling blood pressure and doing this with few side effects.
Heart failure (HF) describes where the heart cannot pump adequately to meet the bodyÍs needs. Mortality remains high; therefore, there is an urgent need for new treatment approaches. The present grant aims to: (1) evaluate treatments for patients at high-risk for future development of HF (2) examine the ability to safely withdraw unnecessary HF drugs (3) focus on the effect of HF on the kidney via novel treatment strategies (4) examine the emerging role of cancer drugs in development of HF.